E

Elucid

AI-powered plaque analysis for cardiovascular imaging

Director of Regulatory

Full-Time
$175k - $225k
Expert
Bachelor's
Boston, MA, USA
HybridBoston-area employees are encouraged to work in the office Mondays and Wednesdays. Fully remote employees outside the Boston area come in as needed.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • At least 7 years of Regulatory Affairs experience in the medical device industry, with successful submissions in the United States and European Union, including pre-submissions, IDEs, 510(k)s, De Novo submissions, and EU MDR product registrations.
  • An advanced degree in Regulatory Affairs, Life Sciences, Engineering, or a software-related discipline.
  • At least 2 years of people-management experience.
  • Expertise in global device regulatory requirements and standards, including 21 CFR Part 820, EU MDR, ISO 13485, ISO 14971, IEC 62304, and IEC 62366.
  • Strong cross-functional collaboration and communication skills, with the ability to translate complex regulatory requirements into actionable guidance and drive effective execution.
Responsibilities
  • Lead execution of regulatory strategy across FDA, EU MDR, and other international markets.
  • Guide regulatory submissions from pre-submission through post-market lifecycle management.
  • Partner closely with Quality, Engineering, Clinical, Commercial, and Product teams.
Desired Qualifications
  • Experience in Software as a Medical Device (SaMD).
  • Familiarity with FDA Class II devices and EU MDR Class IIa/IIb products.

About the company

Elucid Bioimaging provides an AI-powered SaaS platform that helps clinicians assess cardiovascular disease. Its PlaqueIQ tool non-invasively analyzes coronary CT angiography to create a 3D model of arteries and quantify plaque, including high-risk features like lipid-rich necrotic cores, with the AI trained on paired imaging and histology data. The product is regulated, with FDA clearance and CE marking, and it distinguishes itself by grounding its analysis in histology-based references rather than simple image features. The company aims to expand commercialization in North America and Europe to support precision cardiology, preventive treatment, and reduced cardiovascular events.

Company Size

51-200

Company Stage

Series D

Total Funding

$183.3M

Headquarters

Boston, Massachusetts

Founded

2013

Get referred to Elucid

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2, 2026 Series D raised $55 million, lifting total funding to $185 million.
  • Mark Miller joined September 29, 2026 as CRO before BioIntegrated FFR-CT launch.
  • AI-PREDICT enrolled patients July 9, 2026, expanding clinical evidence for lesion-centric risk.

What critics are saying

  • BioIntegrated FFR-CT still sits under FDA 510(k) review, blocking revenue until clearance.
  • Heartflow already owns entrenched FFRCT reimbursement, guidelines, and commercial relationships.
  • One failed pivotal study or adverse FDA decision would strand Elucid as a plaque niche vendor.

What makes Elucid unique

  • Plaque-IQ is validated against ground-truth histology, not visual proxy scoring.
  • Elucid combines Plaque-IQ, BioIntegrated FFR-CT, and lesion-level reporting in one workflow.
  • CPT 75577 and 2026 CMS payment accelerate adoption in imaging centers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Sep 29th, 2026
Elucid hires Mark Miller as CRO ahead of BioIntegrated FFR-CT launch

Elucid, a Boston-based medical technology company developing AI-powered cardiovascular diagnostics software, has appointed Mark Miller as chief revenue officer. Miller will lead the company's commercial expansion ahead of the anticipated FDA clearance of its BioIntegrated FFR-CT software. Miller brings over 25 years of experience in cardiovascular imaging and diagnostics sales. He previously spent a decade at GE Healthcare and Philips, and served as vice president of sales at Cassling, where he led a commercial team of more than 40 professionals. Elucid's platform includes its FDA-cleared Plaque-IQ software and the pending BioIntegrated FFR-CT solution, which helps physicians identify coronary blockages non-invasively. The company focuses on advancing precision diagnosis of cardiovascular disease through AI-enabled image analysis.

Morningstar
Sep 2nd, 2026
Elucid raises $55M in Series D to commercialise AI-powered cardiovascular imaging platform

Elucid, a Boston-based medical technology company, has raised $55 million in an oversubscribed Series D financing round, bringing its total funding to approximately $185 million. The round includes participation from a large medtech company, joining as Elucid's fourth publicly traded strategic investor, alongside IAG Capital Partners and Elevage Medical Technologies. The funding will accelerate commercialisation of Elucid's AI-powered cardiovascular imaging platform. The company is preparing for full commercial launch of its BioIntegrated FFR-CT product, currently under FDA review, alongside its FDA-cleared Plaque-IQ software. Elucid's technology converts routine CT angiography into detailed insights based on plaque biology, vessel anatomy, and physiology, helping clinicians stratify at-risk patients and personalise treatment strategies for atherosclerotic cardiovascular disease.

Associated Press
Apr 15th, 2026
Elucid launches lesion inspection tool for coronary and carotid plaque analysis

Elucid has launched a new Lesion Inspection Tool for its Plaque-IQ software suite, enabling physicians to analyse coronary and carotid plaque composition at the lesion level. The tool provides detailed quantification of plaque types, including high-risk features like lipid-rich necrotic core, supporting more precise clinical decision-making. The Boston-based AI medical technology company's Plaque-IQ is the only plaque analysis technology validated against histology, the gold standard for plaque characterisation. Powered by CT-Virtual Histology, it noninvasively quantifies and classifies coronary and carotid plaque using CTA scans. The tool allows physicians to interrogate any lesion or region and access quantitative results for specific segments, helping identify features associated with heart attack and stroke risk.

HIT Consultant
Jul 22nd, 2024
Elucid Appoints Dr. Kelly Huang As Ceo

Elucid Appoints Dr. Kelly Huang as CEO. by Executive Hires 07/22/2024 Leave a Comment. Dr. Kelly Huang, CEO at ElucidWhat You Should Know: – Elucid, a company pioneering AI-powered medical technology for cardiovascular disease (CVD), has named Dr. Kelly Huang, PhD as its new President and Chief Executive Officer (CEO)

Business Wire
Nov 10th, 2023
Elucid Raises $80 Million in Series C Round Led by Elevage Medical Technologies

Elucid, a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today an